CVS Health sees 2022 profit meeting Street estimates as COVID-19 costs subside
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
Go back to CVS Health sees 2022 profit meeting Street estimates as COVID-19 costs subside
November 3, 2021 1:33 PM EDT
Cantor Fitzgerald analyst Steven Halper raised the price target on CVS Health (NYSE: CVS) to $115.00 (from $95.00) while maintaining an Overweight rating following earnings.
The analyst commented, "We reiterate our Overweight rating on CVS shares and increase our 12-month price target to $115 from $95.... More
November 3, 2021 10:01 AM EDT
CVS Health (NYSE: CVS) today announced that select CVS Pharmacy locations will be offering a two-dose primary series of the Pfizer-BioNTech COVID-19 pediatric vaccine to children ages five to 11 years of age starting on Sunday, 11/7, upon receipt and confirmation of vaccine supply. This follows authorization of the vaccine by the Centers for Disease Control and Prevention (CDC) based on guidance from the organization's Advisory Committee on Immunization Practices and Food and Drug Administration (FDA) Emergency Use Authorization. Parental or legal guardian consent is required for this age group, and children must be... More
